Free Trial

AnaptysBio Q1 2024 Earnings Report

AnaptysBio logo
$14.55 -0.45 (-3.00%)
(As of 12/20/2024 05:23 PM ET)

AnaptysBio EPS Results

Actual EPS
-$1.64
Consensus EPS
-$1.54
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A

AnaptysBio Revenue Results

Actual Revenue
$7.18 million
Expected Revenue
$4.55 million
Beat/Miss
Beat by +$2.63 million
YoY Revenue Growth
N/A

AnaptysBio Announcement Details

Quarter
Q1 2024
Time
N/A
This Crypto Is Set to Explode in December (Ad)

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

AnaptysBio Earnings Headlines

Truist Financial Cuts AnaptysBio (NASDAQ:ANAB) Price Target to $20.00
AnaptysBio price target lowered to $36 from $66 at JPMorgan
This Crypto Is Set to Explode in December
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
Stifel Nicolaus Sticks to Their Buy Rating for AnaptysBio (ANAB)
See More AnaptysBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AnaptysBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AnaptysBio and other key companies, straight to your email.

About AnaptysBio

AnaptysBio (NASDAQ:ANAB), a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

View AnaptysBio Profile

More Earnings Resources from MarketBeat

Upcoming Earnings